Shandong Sito Bio-technology Co., Ltd.'s (SZSE:300583) Largest Shareholders Are Retail Investors Who Were Rewarded as Market Cap Surged CN¥387m Last Week
Shandong Sito Bio-technology Co., Ltd.'s (SZSE:300583) Largest Shareholders Are Retail Investors Who Were Rewarded as Market Cap Surged CN¥387m Last Week
Key Insights
主要见解
- Significant control over Shandong Sito Bio-technology by retail investors implies that the general public has more power to influence management and governance-related decisions
- 52% of the business is held by the top 3 shareholders
- Insiders own 25% of Shandong Sito Bio-technology
- 零售投资者对赛托生物技术的重要控制权意味着普通大众更有影响管理和治理相关决策的权力
- 前三大股东持有该业务的52%。
- 内部人士拥有赛托生物技术25%的股份
Every investor in Shandong Sito Bio-technology Co., Ltd. (SZSE:300583) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are retail investors with 37% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
山东赛托生物技术股份有限公司(SZSE:300583)的每位投资者都应该了解最有影响力的股东群体。而持有最大股份的群体是拥有37%股权的零售投资者。换句话说,该群体将最可能从他们对公司的投资中获益(或蒙受最大损失)。
Clearly, retail investors benefitted the most after the company's market cap rose by CN¥387m last week.
显然,上周公司市值上涨了CN¥38700万后,零售投资者受益最多。
Let's take a closer look to see what the different types of shareholders can tell us about Shandong Sito Bio-technology.
让我们仔细看看不同类型的股东能告诉我们关于赛托生物有什么。

What Does The Institutional Ownership Tell Us About Shandong Sito Bio-technology?
机构持股告诉我们关于赛托生物的什么?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
机构通常在向自己的投资者报告时会针对一个基准进行衡量,因此一旦某只股票被纳入主要指数,他们通常会更加热衷于该股票。我们预计大多数公司都会有一些机构在登记簿上,尤其是那些正在增长的公司。
Shandong Sito Bio-technology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shandong Sito Bio-technology's earnings history below. Of course, the future is what really matters.
赛托生物已经有了机构的股东注册表。 实际上,他们在公司中拥有可观的股份。这可能表明公司在投资社区中具有一定的信誉度。然而,最好对依赖机构投资者所带来的所谓认可保持警惕。他们有时也会犯错。如果多家机构同时改变对一只股票的看法,股价可能会迅速下跌。因此,值得查看下面的赛托生物的收益历史。当然,未来才是真正重要的。

We note that hedge funds don't have a meaningful investment in Shandong Sito Bio-technology. Chao Jie Mi is currently the largest shareholder, with 25% of shares outstanding. For context, the second largest shareholder holds about 23% of the shares outstanding, followed by an ownership of 4.5% by the third-largest shareholder.
我们注意到,对于赛托生物,对冲基金的投资并不重要。周杰民目前是最大股东,持有25%的股份。为了更好地理解,第二大股东持有约23%的股份,第三大股东持有4.5%的股份。
A more detailed study of the shareholder registry showed us that 3 of the top shareholders have a considerable amount of ownership in the company, via their 52% stake.
股东登记簿的更为详细的研究显示,前三大股东持有该公司的52%股权。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is some analyst coverage of the stock, but it could still become more well known, with time.
上海阿拉丁生物化学技术股份有限公司的内部人员拥有重要比例,内部人员在这家总价值27亿人民币的公司中持有12亿人民币的股份。这可能表明创始人仍然拥有很多股份。您可以单击此处查看他们是否进行了买卖。
Insider Ownership Of Shandong Sito Bio-technology
赛托生物的内部所有权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
内部人员的定义在不同国家可能会稍有不同,但董事会成员始终算入其中。公司管理负责经营业务,但即使首席执行官是董事会成员,他或她也必须对董事会负责。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
Our most recent data indicates that insiders own a reasonable proportion of Shandong Sito Bio-technology Co., Ltd.. Insiders own CN¥722m worth of shares in the CN¥2.9b company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.
我们最近的数据显示,内部持有合理比例的赛托生物股份有限公司股份。 内部持有该29亿人民币公司中价值72200万人民币的股份。看到内部人员对业务如此投入是很好的。也许值得检查一下这些内部人员最近是否一直在买入。
General Public Ownership
一般大众所有权
The general public-- including retail investors -- own 37% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
总体来说,包括零售投资者在内的大众拥有公司的37%股份,因此不能轻易被忽视。尽管这种所有权规模可能不足以在他们的任何决策中左右政策,但他们仍然可以对公司政策产生集体影响。
Private Company Ownership
私有公司的所有权
It seems that Private Companies own 29%, of the Shandong Sito Bio-technology stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
山东赛托生物的29%股权由私营企业持有。仅凭这一事实很难得出任何结论,因此值得研究一下这些私营企业的所有者是谁。有时内部人员或其他相关方通过单独的私营公司对一家上市公司的股份感兴趣。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 2 warning signs for Shandong Sito Bio-technology that you should be aware of.
虽然考虑拥有一家公司的不同群体是值得的,但有更重要的因素。例如,我们已经确定了山东赛托生物存在2个警示信号,您应该注意。
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但最终,决定该业务所有者将获得多大利益的是未来而非过去。因此,我们认为最好查看此免费报告,以了解分析师是否预测更光明的未来。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。